 |
 |
||||||||
|
|||||||||
|
|||||||||
 |
 |
||||||||
|
 |
Tetracycline (“TET”) Program Paratek is applying proprietary chemistries to modify existing antibiotics in order to circumvent or block the resistance mechanisms employed by bacteria. Paratek has developed and obtained patent protection for over 1,000 proprietary derivatives of the well-known antibiotic tetracycline to date. Importantly, Paratek’s new tetracyclines can inhibit bacteria that are known to be resistant to existing antibiotics. Some of Paratek’s tetracycline derivatives are bactericidal (kill bacteria), while classic tetracyclines are bacteriostatic (stop growth of bacteria). In both in vitro and in vivo studies, Paratek’s new compounds have been shown to be highly potent, and yet have maintained excellent toxicity and safety profiles. Paratek is currently focused on developing novel tetracyclines for use in different antibiotic indications. Paratek is also developing proprietary tetracycline derivatives for a number of other antibacterial and non-antibacterial uses, including ophthalmic and dermatologic uses and as antiparasitic and antifungal agents.
|
